+32 (0)470 11 49 92
iTeos Therapeutics is a publicly-held (NASDAQ: ITOS), clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies.
Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (UCLouvain) in 2011.
In March 2020, the Company completed a $125 million Series B2 financing, and in July 2020, we completed our IPO raising over $230million of gross proceeds. In June 2021, iTeos entered into a transformative $2.145 billion co-development and co-commercialization agreement with GSK for EOS-448, iTeos’s anti-TIGITmonoclonal antibody. As a well-capitalized biotech company iTeos is positioned to continue to develop our clinical pipeline and maintain our investments in our discovery research team to leverage our fantastic science to improve the lives of cancer patients.
For more information, please visit www.iteostherapeutics.com.
iTeos Therapeutics is now a world-class biotech in cancer immunotherapy. To carry on its growth, expand its pipeline and reinforce its team, iTeos Therapeutics is looking for a Scientist Scientist – Medicinal Chemistry.
iTeos Therapeutics, focused on developing innovative immuno-oncology therapies, is seeking a highly motivated Senior Scientist in Medicinal Chemistry to help advance preclinical projects. In addition, the candidate will aid in setting up and play a key role in the new, state of the art, medicinal chemistry facility at iTeos. The ideal candidate will have >6 years of experience in a biotech or pharma company and will possess experience in the field of medicinal chemistry.
Your application and related information will remain strictly confidential.